SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
11496095
Source:
http://linkedlifedata.com/resource/pubmed/id/11496095
Search
Subject
(
61
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0024485
,
umls-concept:C0031809
,
umls-concept:C0450442
,
umls-concept:C0675791
,
umls-concept:C0754820
,
umls-concept:C1533685
pubmed:issue
7
pubmed:dateCreated
2001-8-9
pubmed:abstractText
A series of preclinical tests were undertaken during the developmental process to determine the safety profile of gadoversetamide injection (OptiMARK).
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/0045377
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Contrast Media
,
http://linkedlifedata.com/resource/pubmed/chemical/Organometallic Compounds
,
http://linkedlifedata.com/resource/pubmed/chemical/gadoversetamide
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0020-9996
pubmed:author
pubmed-author:AdamsM DMD
,
pubmed-author:BarcoS JSJ
,
pubmed-author:GalenK PKP
,
pubmed-author:HynesM RMR
,
pubmed-author:MacDonaldJ RJR
,
pubmed-author:PeriasamyM PMP
,
pubmed-author:TroupC MCM
,
pubmed-author:Wible J HJHJr
,
pubmed-author:WojdylaJ KJK
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
401-12
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed-meshheading:11496095-Abnormalities, Drug-Induced
,
pubmed-meshheading:11496095-Animals
,
pubmed-meshheading:11496095-Blood Cells
,
pubmed-meshheading:11496095-Cardiovascular System
,
pubmed-meshheading:11496095-Contrast Media
,
pubmed-meshheading:11496095-Dogs
,
pubmed-meshheading:11496095-Dose-Response Relationship, Drug
,
pubmed-meshheading:11496095-Drug Evaluation, Preclinical
,
pubmed-meshheading:11496095-Female
,
pubmed-meshheading:11496095-Fertility
,
pubmed-meshheading:11496095-Fetus
,
pubmed-meshheading:11496095-Injections, Intravenous
,
pubmed-meshheading:11496095-Lethal Dose 50
,
pubmed-meshheading:11496095-Magnetic Resonance Imaging
,
pubmed-meshheading:11496095-Male
,
pubmed-meshheading:11496095-Mice
,
pubmed-meshheading:11496095-Mice, Inbred ICR
,
pubmed-meshheading:11496095-Mutagenesis
,
pubmed-meshheading:11496095-Organometallic Compounds
,
pubmed-meshheading:11496095-Pregnancy
,
pubmed-meshheading:11496095-Rats
,
pubmed-meshheading:11496095-Rats, Sprague-Dawley
,
pubmed-meshheading:11496095-Toxicity Tests
pubmed:year
2001
pubmed:articleTitle
Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging.
pubmed:affiliation
Mallinckrodt Imaging, St. Louis, Missouri 63134, USA. jhwible@mkg.com
pubmed:publicationType
Journal Article